Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids.

Autor: Colín-Lozano B; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. clbi_ff@uaem.mx., Estrada-Soto S; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. enoch@uaem.mx., Chávez-Silva F; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. facasy@gmail.com., Gutiérrez-Hernández A; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. ghaa_ff@uaem.mx., Cerón-Romero L; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. crlc_ff@uaem.mx., Giacoman-Martínez A; Laboratorio de Farmacología, Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México 09340, Mexico. agmfest@hotmail.com., Almanza-Pérez JC; Laboratorio de Farmacología, Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México 09340, Mexico. j.almanza.perez@gmail.com., Hernández-Núñez E; Cátedra CONACyT, Departamento de Recursos del Mar, Centro de Investigación y de Estudios Avanzados del IPN, Unidad Mérida, Yucatán 97310, Mexico. emanuel.hernandez@cinvestav.mx., Wang Z; CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China, endlesslily@hotmail.com (Z.W.). endlesslily@hotmail.com., Xie X; CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China, endlesslily@hotmail.com (Z.W.). xxie@simm.ac.cn., Cappiello M; Dipartimento di Biologia, Unità di Biochimica, University of Pisa, 56126 Pisa, Italy. mcappiello@biologia.unipi.it., Balestri F; Dipartimento di Biologia, Unità di Biochimica, University of Pisa, 56126 Pisa, Italy. francesco.balestri@unipi.it., Mura U; Dipartimento di Biologia, Unità di Biochimica, University of Pisa, 56126 Pisa, Italy. umberto.mura@unipi.it., Navarrete-Vazquez G; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico. gabriel_navarrete@uaem.mx.
Jazyk: angličtina
Zdroj: Molecules (Basel, Switzerland) [Molecules] 2018 Feb 06; Vol. 23 (2). Date of Electronic Publication: 2018 Feb 06.
DOI: 10.3390/molecules23020340
Abstrakt: We have synthesized a small series of five 3-[4-arylmethoxy)phenyl]propanoic acids employing an easy and short synthetic pathway. The compounds were tested in vitro against a set of four protein targets identified as key elements in diabetes: G protein-coupled receptor 40 (GPR40), aldose reductase (AKR1B1), peroxisome proliferator-activated receptor gama (PPARγ) and solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT-4). Compound 1 displayed an EC 50 value of 0.075 μM against GPR40 and was an AKR1B1 inhibitor, showing IC 50 = 7.4 μM. Compounds 2 and 3 act as slightly AKR1B1 inhibitors, potent GPR40 agonists and showed an increase of 2 to 4-times in the mRNA expression of PPARγ, as well as the GLUT-4 levels. Docking studies were conducted in order to explain the polypharmacological mode of action and the interaction binding mode of the most active molecules on these targets, showing several coincidences with co-crystal ligands. Compounds 1 - 3 were tested in vivo at an explorative 100 mg/kg dose, being 2 and 3 orally actives, reducing glucose levels in a non-insulin-dependent diabetes mice model. Compounds 2 and 3 displayed robust in vitro potency and in vivo efficacy, and could be considered as promising multitarget antidiabetic candidates. This is the first report of a single molecule with these four polypharmacological target action.
Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje